ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), began enrolling patients in its Phase 2 clinical trial of merimepodib for the treatment of COVID-19.
Merimepodib is an orally administered, broad-spectrum antiviral agent. In in vitro studies, when combined with remdesivir, merimepodib reduced SARS-CoV-2 replication to undetectable levels.
The trial will enroll some 40 adults with advanced COVID-19 who will receive either 400 mg of merimepodib every eight hours for 10 days, or placebo. The primary endpoint is the proportion of subjects alive at day 28 who are not hospitalized, or if hospitalized, are free of respiratory failure.
“Three of our four trial sites where our partners are enrolling patients are in the recognized hot spots of Texas, Arizona, and Florida,” Kenneth Londoner, chairman and CEO of BioSig, said in a statement.
“The patients in this trial are hospitalized and requiring oxygen; therefore, providing effective treatment is of the utmost importance to all,” he added.
